Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 8 of 18
Next
>>
>
176 to 200 of 432 records
per page:

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GEC50	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	EC50	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
Hs 578T	Omipalisib	3		sigmoid	sigmoid	Hs578T omipalisib 3	8	2.869	0.0255	-0.107	0.615	0.0533	-0.22	0.494	0.99	8.79e-07	NA	0.0145	0.0989	0.392	0.0102	0.0968	0.62	0.993	3.4e-07	NA
HCC38	Omipalisib	3	72	sigmoid	sigmoid	HCC38 omipalisib 0 3 72	8	1.446	0.0145	-0.503	0.802	0.0539	-0.597	0.6	0.993	3.08e-07	NA	0.0449	0.134	0.499	0.0308	0.107	0.644	0.993	2.98e-07	NA
HCC38	Torin2	3	72	sigmoid	sigmoid	HCC38 Torin2 0 3 72	8	1.385	0.013	-0.624	0.855	0.0547	-0.706	0.615	0.996	8.13e-08	NA	0.0407	0.0986	0.484	0.0311	0.0829	0.669	0.997	3.31e-08	NA
BT-20	Dactolisib	1	72	sigmoid	sigmoid	BT20 dactolisib 0 1 72	8	2.055	0.0223	-0.205	0.652	0.0609	-0.33	0.505	0.979	9.18e-06	NA	0.0305	0.15	0.475	0.0171	0.153	0.631	0.979	9.75e-06	NA
BT-20	GDC-0980	2	72	sigmoid	sigmoid	BT20 apitolisib 0 2 72	8	1.659	0.0456	-0.414	0.639	0.0629	-0.33	1.58	0.993	4.18e-07	NA	0.0641	0.131	0.575	0.0506	0.168	1.74	0.995	1.2e-07	NA
Hs 578T	Torin2	1		sigmoid	sigmoid	Hs578T Torin2 1	8	2.031	0.015	-0.405	0.761	0.0631	-0.56	0.522	0.992	5.31e-07	NA	0.021	0.0851	0.419	0.0163	0.0756	0.64	0.993	3.63e-07	NA
HCC38	Torin2	2	72	sigmoid	sigmoid	HCC38 Torin2 0 2 72	8	2.140	0.0146	-0.48	0.793	0.0654	-0.634	0.545	0.993	3.78e-07	NA	0.0176	0.056	0.391	0.015	0.0502	0.68	0.989	1.33e-06	NA
BT-20	Torin1	1	72	sigmoid	sigmoid	BT20 Torin1 0 1 72	8	2.022	0.0383	-0.105	0.566	0.0658	-0.179	0.565	0.991	7.45e-07	NA	0.0591	0.197	0.536	0.0286	0.182	0.624	0.994	2.54e-07	NA
BT-549	Trametinib	2	72	sigmoid	sigmoid	BT549 trametinib 0 2 72	8	1.914	Inf	0.602	0.2	0.0685	0.581	0.837	0.995	1.05e-07	NA	Inf	0.654	0.822	0.0601	0.638	0.839	0.995	1.04e-07	NA
Hs 578T	MK2206	2		sigmoid	sigmoid	Hs578T MK-2206 2	8	2.530	Inf	0.664	0.131	0.0699	0.752	1.34	0.75	0.0156	NA	Inf	0.628	0.848	0.0616	0.717	1.21	0.767	0.0126	NA
HCC70	Everolimus	3	72	sigmoid	sigmoid	HCC70 everolimus 0 3 72	8	2.401	530906.0	0.749	0.195	0.072	0.603	0.1	0.706	0.0255	NA	381983.0	0.725	0.782	0.0137	0.59	0.1	0.706	0.0255	NA
HCC1806	Torin2	1	72	sigmoid	sigmoid	HCC1806 Torin2 0 1 72	8	2.759	0.0569	-0.203	0.582	0.0763	-0.234	1.3	0.996	6.76e-08	NA	0.0486	0.079	0.492	0.0442	0.0528	1.17	0.995	1.09e-07	NA
HCC1806	Torin2	2	72	sigmoid	sigmoid	HCC1806 Torin2 0 2 72	8	2.843	0.0589	-0.181	0.57	0.0771	-0.211	1.3	0.996	6.72e-08	NA	0.0486	0.079	0.492	0.0442	0.0528	1.17	0.995	1.08e-07	NA
HCC1806	Torin2	3	72	sigmoid	sigmoid	HCC1806 Torin2 0 3 72	8	3.212	0.0678	-0.0927	0.522	0.0798	-0.12	1.32	0.996	6.56e-08	NA	0.0486	0.079	0.492	0.0442	0.0528	1.17	0.995	1.09e-07	NA
Hs 578T	MK2206	1		sigmoid	sigmoid	Hs578T MK-2206 1	8	2.039	Inf	0.608	0.165	0.087	0.665	2.09	0.9	0.00101	NA	Inf	0.641	0.845	0.0803	0.689	1.9	0.908	0.000775	NA
BT-549	MK2206	1	72	sigmoid	sigmoid	BT549 MK-2206 0 1 72	8	1.811	Inf	0.632	0.189	0.103	0.58	0.8	0.911	0.000695	NA	Inf	0.692	0.839	0.101	0.642	0.73	0.911	0.000717	NA
BT-20	Trametinib	3	72	sigmoid	sigmoid	BT20 trametinib 0 3 72	8	2.539	Inf	0.64	0.208	0.104	0.541	0.392	0.967	3.69e-05	NA	Inf	0.604	0.761	0.0656	0.513	0.391	0.964	4.56e-05	NA
BT-549	MK2206	2	72	sigmoid	sigmoid	BT549 MK-2206 0 2 72	8	1.871	Inf	0.926	0.0188	0.107	0.926	5.0	0.816	0.00627	NA	Inf	0.932	0.983	0.107	0.931	5.0	0.809	0.00694	NA
BT-20	GDC-0980	3	72	sigmoid	sigmoid	BT20 apitolisib 0 3 72	8	2.502	0.0976	-0.115	0.437	0.107	-0.0716	1.53	0.994	2.41e-07	NA	0.0894	0.13	0.62	0.0732	0.163	1.96	0.996	6.83e-08	NA
BT-549	Trametinib	3	72	sigmoid	sigmoid	BT549 trametinib 0 3 72	8	1.755	Inf	0.553	0.223	0.107	0.505	0.899	0.942	0.000194	NA	Inf	0.642	0.817	0.104	0.595	0.804	0.938	0.000236	NA
Hs 578T	Torin2	2		sigmoid	sigmoid	Hs578T Torin2 2	8	2.528	0.0153	-0.467	0.778	0.112	-0.771	0.47	0.986	2.55e-06	NA	0.0122	0.0353	0.352	0.0109	0.036	0.668	0.984	4.09e-06	NA
HCC38	XL147	3	72	sigmoid	sigmoid	HCC38 pilaralisib 0 3 72	8	1.420	Inf	0.909	0.0219	0.114	0.921	5.0	0.815	0.00631	NA	Inf	0.936	0.985	0.114	0.945	5.0	0.813	0.00654	NA
BT-549	MK2206	3	72	sigmoid	sigmoid	BT549 MK-2206 0 3 72	8	1.685	Inf	0.714	0.131	0.123	0.711	3.44	0.953	0.000102	NA	Inf	0.771	0.895	0.123	0.768	3.25	0.949	0.000136	NA
BT-20	GDC-0980	1	72	sigmoid	sigmoid	BT20 apitolisib 0 1 72	8	2.001	0.0935	-0.289	0.498	0.128	-0.251	1.29	0.994	2.71e-07	NA	0.113	0.126	0.62	0.0885	0.151	1.48	0.996	7.34e-08	NA
BT-549	Trametinib	1	72	sigmoid	sigmoid	BT549 trametinib 0 1 72	8	1.812	Inf	0.596	0.202	0.131	0.523	0.61	0.959	6.65e-05	NA	28.3	0.664	0.828	3.47	0.254	0.337	0.933	0.000305	NA

|<
<<
Previous
Page 8 of 18
Next
>>
>
176 to 200 of 432 records
per page:

HMS LINCS Project

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)